Premium
Objective score of atopic dermatitis and prebiotic in infant (382.8)
Author(s) -
Ghanei Nila,
Siassi Fereydoun,
Zandieh Fariborz
Publication year - 2014
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.28.1_supplement.382.8
Subject(s) - prebiotic , atopic dermatitis , medicine , scorad , placebo , fructooligosaccharide , allergy , randomized controlled trial , pediatrics , dermatology , dermatology life quality index , disease , immunology , food science , chemistry , alternative medicine , pathology
Background: Atopic dermatitis (AD) is a prevalent medical condition in infants aging from 6 months to 12 years old. Due to changes in life style, the prevalence of AD has been on the rise in recent decades such that nearly 50% of children in the first year of life and 80% in the first five years suffer from it. AD can lead to many complications such as changes in behavior, drowsiness, and susceptibility to viral and bacterial infections. Current standard of care for AD includes treatment with corticosteroids. However, treatment with corticosteroids can lead to many complications. There is a need for alternative treatments with lower risks of side effects. The aim of this study was to determine the effect of prebiotic supplement on objective score of infant with AD. Material and methods: Seventy 7‐24 month old infants with AD were enrolled in a double‐blind placebo‐controlled trial and were divided into 2 groups. The prebiotic supplemented group (PS) received fructooligosaccharides‐inulin and the control supplemented group (CS) received maltodextrin powder as placebo for 3 months. At the beginning and at the end of intervention total SCORAD (SCORing for Atopic Dermatitis) questionnaire was completed by a physician and serum levels of IgE were measured. The data were analyzed using SPSS software. Table: Clinical parameters before and after prebiotic supplementation in atopic dermatitis infantsGROUPvariable Intervention(PS)N=35 Control(CS)N=35 P value Objective scoreBeforeafter 55.4±97.73.8±8.1 32.8±16.715.5±9.8 0.180.001 Total SCORAD:Before After 53.9±23.64.3±9.6 43.4±20.919.4±13 0.060.001 Serum IgE level (IU/ml)Beforeafter 160±73107±42.7 158±4093±56 0.340.001Results : The objective SCORAD consist of just the extent and intensity items. All clinical parameters of the SCORAD decreased significantly in both groups at the end of trial. However, the reduction in the PS group was significantly higher than the CS group (P<0.001). Also Significant negative correlation was found between total SCORAD score and Serum IgE levels (r 2 =0.20 ; P<0.001). Conclusion: It seems that prebiotic supplement can effectively reduce clinical signs in AD infants. Grant Funding Source : supported by Tehran University of Medical Sciences (TUMS)